Ezabenlimab plus mDCF Induction and Adaptive Chemoradiotherapy Achieve High Complete Response Rates in Stage 3 Squamous Cell Anal Carcinoma (INTERACT-ION)
Posted innews Oncology Radiology

Ezabenlimab plus mDCF Induction and Adaptive Chemoradiotherapy Achieve High Complete Response Rates in Stage 3 Squamous Cell Anal Carcinoma (INTERACT-ION)

The INTERACT-ION phase 2 trial reports that induction ezabenlimab with modified DCF followed by biomarker-guided, involved-node radiotherapy produced high clinical complete response rates (overall 77.8%) with a manageable safety profile in stage 3 anal squamous cell carcinoma.
Comparative Efficacy of Induction-Concurrent Versus Concurrent-Adjuvant Chemoradiotherapy in High-Risk N2-N3 Nasopharyngeal Carcinoma: Insights from a Phase 3 Randomized Trial
Posted inOncology Radiology Specialties

Comparative Efficacy of Induction-Concurrent Versus Concurrent-Adjuvant Chemoradiotherapy in High-Risk N2-N3 Nasopharyngeal Carcinoma: Insights from a Phase 3 Randomized Trial

A phase 3 trial showed no significant difference in 3-year progression-free survival between induction-concurrent and concurrent-adjuvant chemoradiotherapy in treating high-risk N2-N3 nasopharyngeal carcinoma, with both regimens exhibiting manageable safety profiles.